Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Urothelial Cancer

Clinical Trial at: Compass Oncology - Vancouver

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: Urothelial Cancer
USOR Number: 19094

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Compass Oncology - Tigard

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: Urothelial Cancer
USOR Number: 19094

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Compass Oncology - Portland

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: Urothelial Cancer
USOR Number: 19094

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Compass Oncology - Portland

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: Urothelial Cancer
USOR Number: 19094

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page

Solid Tumors

Clinical Trial at: Compass Oncology - Vancouver

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

  • Details

ClinicalTrials.gov ID: NCT04083976
Diagnosis Type: Solid Tumors
USOR Number: 19092

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Solid Tumors

Clinical Trial at: Compass Oncology - Tigard

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

  • Details

ClinicalTrials.gov ID: NCT04083976
Diagnosis Type: Solid Tumors
USOR Number: 19092

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Solid Tumors

Clinical Trial at: Compass Oncology - Portland

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

  • Details

ClinicalTrials.gov ID: NCT04083976
Diagnosis Type: Solid Tumors
USOR Number: 19092

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Solid Tumors

Clinical Trial at: Compass Oncology - Portland

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

  • Details

ClinicalTrials.gov ID: NCT04083976
Diagnosis Type: Solid Tumors
USOR Number: 19092

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page

Solid Tumors

Clinical Trial at: Compass Oncology - Tigard

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Details

ClinicalTrials.gov ID: NCT03822117
Diagnosis Type: Solid Tumors
USOR Number: 19079

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Solid Tumors

Clinical Trial at: Compass Oncology - Vancouver

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Details

ClinicalTrials.gov ID: NCT03822117
Diagnosis Type: Solid Tumors
USOR Number: 19079

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page
1 2 3 4 5 … 12

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.